Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says

MT Newswires Live08-04

Viking Therapeutics (VKTX) could unlock substantial additional opportunities for VK2735 through less frequent injections, oral maintenance therapy, switching patients from other weight-loss drugs and combination treatments, Oppenheimer said.

Upcoming data in Q3 and 2027 could show whether VK2735 can support less frequent injectable dosing and oral dosing in a maintenance setting, the investment firm said in a Sunday note.

Oppenheimer said patients taking semaglutide or tirzepatide could potentially switch to VK2735 with limited side effects if physicians use appropriate starting doses and timing, adding that its maintenance approach could support long-term treatment through steadier drug exposure and improved tolerability.

Incorrect starting doses and poorly timed breaks between treatments remain the main risks when switching patients to VK2735, the note added.

Oppenheimer has an outperform rating and a $100 price target on Viking Therapeutics, adding that an oral combination of VK2735 and VK3019 could target weight loss through three complementary pathways in a single pill.

Shares of Viking Therapeutics were up 2.3% in Monday trading.

Price: 32.47, Change: +0.73, Percent Change: +2.30

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656303982?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 00:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656303982","market":"nz","top_or_hot":-1,"title":"Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VKTX) could unlock substantial additional opportunities for VK2735 through less frequent injections, oral maintenance therapy, switching patients from other weight-loss drugs and combination treatments, Oppenheimer said.</p><p>Upcoming data in Q3 and 2027 could show whether VK2735 can support less frequent injectable dosing and oral dosing in a maintenance setting, the investment firm said in a Sunday note.</p><p>Oppenheimer said patients taking semaglutide or tirzepatide could potentially switch to VK2735 with limited side effects if physicians use appropriate starting doses and timing, adding that its maintenance approach could support long-term treatment through steadier drug exposure and improved tolerability.</p><p>Incorrect starting doses and poorly timed breaks between treatments remain the main risks when switching patients to VK2735, the note added.</p><p>Oppenheimer has an outperform rating and a $100 price target on Viking Therapeutics, adding that an oral combination of VK2735 and VK3019 could target weight loss through three complementary pathways in a single pill.</p><p>Shares of Viking Therapeutics were up 2.3% in Monday trading.</p><p>Price: 32.47, Change: +0.73, Percent Change: +2.30</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-04 00:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VKTX) could unlock substantial additional opportunities for VK2735 through less frequent injections, oral maintenance therapy, switching patients from other weight-loss drugs and combination treatments, Oppenheimer said.</p><p>Upcoming data in Q3 and 2027 could show whether VK2735 can support less frequent injectable dosing and oral dosing in a maintenance setting, the investment firm said in a Sunday note.</p><p>Oppenheimer said patients taking semaglutide or tirzepatide could potentially switch to VK2735 with limited side effects if physicians use appropriate starting doses and timing, adding that its maintenance approach could support long-term treatment through steadier drug exposure and improved tolerability.</p><p>Incorrect starting doses and poorly timed breaks between treatments remain the main risks when switching patients to VK2735, the note added.</p><p>Oppenheimer has an outperform rating and a $100 price target on Viking Therapeutics, adding that an oral combination of VK2735 and VK3019 could target weight loss through three complementary pathways in a single pill.</p><p>Shares of Viking Therapeutics were up 2.3% in Monday trading.</p><p>Price: 32.47, Change: +0.73, Percent Change: +2.30</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OZEM","symbol_name":"Roundhill GLP-1 & Weight Loss ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656303982","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656303982","pubTimestamp":1785775454,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Viking Therapeutics (VKTX) could unlock substantial additional opportunities for VK2735 through less frequent injections, oral maintenance therapy, switching patients from other weight-loss drugs and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OZEM":"Roundhill GLP-1 & Weight Loss ETF","OPY":"奥本海默控股","BK4599":"减肥药","BK4588":"碎股","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","BK4585":"ETF&股票定投概念","BK4127":"投资银行业与经纪业","VKTX":"Viking Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"奥本海默表示，Viking Therapeutics 的 VK2735 带来了巨大的可选性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1.5,"OZEM":0.6,"THNR":0.6,"OPY":1.5},"content_text":"Viking Therapeutics (VKTX) could unlock substantial additional opportunities for VK2735 through less frequent injections, oral maintenance therapy, switching patients from other weight-loss drugs and combination treatments, Oppenheimer said.Upcoming data in Q3 and 2027 could show whether VK2735 can support less frequent injectable dosing and oral dosing in a maintenance setting, the investment firm said in a Sunday note.Oppenheimer said patients taking semaglutide or tirzepatide could potentially switch to VK2735 with limited side effects if physicians use appropriate starting doses and timing, adding that its maintenance approach could support long-term treatment through steadier drug exposure and improved tolerability.Incorrect starting doses and poorly timed breaks between treatments remain the main risks when switching patients to VK2735, the note added.Oppenheimer has an outperform rating and a $100 price target on Viking Therapeutics, adding that an oral combination of VK2735 and VK3019 could target weight loss through three complementary pathways in a single pill.Shares of Viking Therapeutics were up 2.3% in Monday trading.Price: 32.47, Change: +0.73, Percent Change: +2.30","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656303982","isCrawlerRequest":true}